Tatva Chintan Pharma Chem Ltd (TATVA) — FY26 Annual Report | 27 August 2026

Tatva Chintan Pharma Chem Ltd (TATVA) reported FY2025-26 revenue of ₹5,058.58 crore, up from ₹3,699.76 crore, driven by growth in specialty chemicals. PAT margin improved to 18.42% with profit after tax at ₹390.82 crore. The company proposed a final dividend of ₹2 per share (₹46.78 crore total) and increased borrowing limits to ₹1,000 crore. Key growth drivers include SDA (71% YoY growth) and electrolyte salts (174% YoY growth), supported by expansion in Dahej GIDC facility. Sustainability initiatives include 3.2 MW wind-solar hybrid power and Zero Liquid Discharge status. The Board reappointed three whole-time directors for 3-year terms starting February 2027, with remuneration of [amount not verified] each. The company maintains strong ESG compliance, ISO certifications, and no material regulatory penalties.